LRMR
Larimar Therapeutics Inc

4,979
Mkt Cap
$466.43M
Volume
2.84M
52W High
$6.42
52W Low
$1.61
PE Ratio
-2.03
LRMR Fundamentals
Price
$4.49
Prev Close
$4.47
Open
$4.52
50D MA
$3.96
Beta
1.61
Avg. Volume
9.57M
EPS (Annual)
-$2.27
P/B
4.78
Rev/Employee
$0.00
$145.15
Loading...
Loading...
News
all
press releases
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Up 8.2% After Analyst Upgrade
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Up 8.2% After Analyst Upgrade...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Wedbush Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $13.00
Wedbush lifted their price target on shares of Larimar Therapeutics from $12.00 to $13.00 and gave the stock an "outperform" rating in a research note on Friday...
MarketBeat·2d ago
News Placeholder
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Sees Significant Decrease in Short Interest
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) saw a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 7,692,689...
MarketBeat·6d ago
News Placeholder
Mangrove Partners IM LLC Sells 327,997 Shares of Larimar Therapeutics, Inc. $LRMR
Mangrove Partners IM LLC decreased its position in Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 42.6% during the third quarter, according to its most recent disclosure with the...
MarketBeat·8d ago
News Placeholder
Investors Purchase Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR)
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) was the recipient of some unusual options trading activity on Friday. Traders acquired 3,011 call options on the stock. This is an increase...
MarketBeat·8d ago
News Placeholder
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Down 8% - Should You Sell?
Larimar Therapeutics (NASDAQ:LRMR) Trading Down 8% - Here's Why...
MarketBeat·9d ago
News Placeholder
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
Zacks·15d ago
News Placeholder
Larimar Therapeutics (NASDAQ:LRMR) Price Target Raised to $12.00
Wedbush lifted their price target on shares of Larimar Therapeutics from $11.00 to $12.00 and gave the stock an "outperform" rating in a research note on Tuesday...
MarketBeat·18d ago
News Placeholder
James Flynn Acquires 5,000,000 Shares of Larimar Therapeutics (NASDAQ:LRMR) Stock
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Get Free Report) Director James Flynn acquired 5,000,000 shares of Larimar Therapeutics stock in a transaction on Friday, February 27th. The shares were...
MarketBeat·19d ago
News Placeholder
What is Lifesci Capital's Estimate for LRMR FY2025 Earnings?
Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities researchers at Lifesci Capital issued their FY2025 EPS estimates for Larimar Therapeutics in a note issued to investors on Tuesday...
MarketBeat·24d ago
<
1
2
...
>

Latest LRMR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.